At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
SAF312 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Vehicle-controlled, Subject and Investigator-masked, Proof-of-concept Study to Evaluate the Use of Topical Ocular SAF312 in the Treatment of Postoperative Ocular Pain in Patients Undergoing Photorefractive Keratectomy (PRK) Surgery
In Brief
A Phase 2 clinical trial evaluating SAF312 and Placebo for Postoperative Ocular Pain After PRK Surgery. Completed, enrolled 40 participants across 4 sites.
Detailed Summary
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as after photorefractive keratectomy (PRK) surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionJan 2018
Study CompletionFeb 2018
TodayJul 2026
First PostedNov 10, 2016
Enrollment StartDec 1, 2016
Primary CompletionJan 15, 2018
Study CompletionFeb 21, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.6 years ago
Interventions
SAF312drug
Placebodrug